Sally Gu advises clients on Food and Drug Administration (FDA) advertising and promotion issues, compliance with current good manufacturing practices (cGMP), life cycle management, and product development issues. 

She routinely advises pharmaceutical companies on pre-launch and post-marketing advertising and promotion issues and has served on multiple promotional review committees.  She also assists pharmaceutical clients with responses to FDA enforcement actions and related government investigations, and advises on FDA regulatory issues arising in corporate transactional matters and filings with the Securities and Exchange Commission (SEC).

While at University of Michigan Law School, Sally was a Notes Editor for the Michigan Law Review, and the President of the Michigan Health Law Organization.

In addition to assisting clients in the life sciences and health care industry, Sally is also active in the firm's Pro Bono practice.